ny-eso-1
2 articles tagged with ‘ny-eso-1’
NY-ESO-1 Peptide Clinical Trial: A Research Guide to Cancer/Testis Antigens
NY-ESO-1 (cancer/testis antigen 1B) is one of the most immunogenic proteins known and a central target in peptide-based cancer immunotherapy clinical trials. This article explains the biology of NY-ESO-1, key epitope clusters used in research, and how researchers can validate peptide tools for TCR-T cell therapy, cancer vaccines, and immune monitoring.
Cancer-Testis Antigens: Targets for Immunotherapy Research
Cancer-Testis Antigens (CTAs) are normally restricted to germline tissues like testis or placenta, which are immune-privileged and lack MHC class I expression. Their aberrant expression in various cancers makes them ideal targets for immunotherapy due to minimal expression in normal somatic tissues. This article focuses on two key CTAs, NY-ESO-1 and PRAME, and their roles in T-cell-based immunotherapy.